Event Date & Time

Date: June 25, 2026

Time: 7:00 AM PT, 10:00 AM EDT, 4:00 PM CET

Abstract

As CAR-T therapies continue to evolve, both viral and non-viral delivery systems are emerging as powerful platforms for nucleic acid delivery and cellular engineering. 

However, the successful development, optimisation, and translation of these complex delivery systems depends heavily on access to precise, high-resolution analytical technologies. In this webinar, we will demonstrate how nano-flow cytometry (NanoFCM) has become an essential tool for the characterisation of both viral vectors and non-viral nanoparticles, delivering critical single-particle insights that conventional techniques often cannot achieve. 

Attendees will learn how NanoFCM enables accurate measurement of particle size, concentration, purity, cargo encapsulation efficiency, and ligand quantification at the single-particle level. These capabilities support process control, enhanced reproducibility, and accelerated development of next-generation CAR-T therapies. 

Through real-world applications, we will showcase the growing role of NanoFCM as a foundational analytical platform for advanced cell and gene therapy workflows.

Learning Objectives

• Understand the analytical challenges of viral and non-viral delivery systems for CAR-T cellular engineering.
• Learn how NanoFCM enables high-resolution characterisation of nanoparticle delivery systems at the single-particle level.
• Explore how NanoFCM supports process optimisation, quality control, and workflows in next-generation CAR-T development.

🔗 Register Now:

Advancing CAR-T Development With NanoFCM: Characterising Viral and Non-Viral Delivery Systems

Speaker Bio

Dr Genevieve Anghileri, Ph.D

Field Application Scientist

NanoFCM

Genevieve Anghileri is a Field Application Scientist (FAS) at NanoFCM, aiding in the implementation of nano-flow cytometry for a multitude of applications including biological and non-biological nanoparticles. I have many years of experience in comprehensive nanoparticle analysis, completing a PhD in EV engineering for novel therapeutic platforms.